Status:
COMPLETED
Neuroprotective Effects of Xenon Treatment in Patients with Cerebral Infarction
Lead Sponsor:
Negovsky Reanimatology Research Institute
Conditions:
Ischemic Stroke
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
In the Russian Federation, ischemic cerebral infarction is recorded annually in more than 450,000 people. It is the second most common cause of death after coronary heart disease. The 30-day mortalit...
Detailed Description
In the Russian Federation, ischemic cerebral infarction is recorded annually in more than 450,000 people. It is the second most common cause of death after coronary heart disease. The 30-day mortalit...
Eligibility Criteria
Inclusion
- Age \> 18;
- Ischemic stroke with a NIHSS score at the time of hospitalization from 5 to 15 points
- Score on the Glasgow coma scale ≥ 13 points
- Assessment of the patient no later than 8 hours after the appearance of the first signs of ONMC
- Signed voluntary informed consent to participate in the study.
Exclusion
- Myocardial infarction in the previous 6 months
- Body mass index \> 35 kg/m2
- Class of chronic kidney disease ≥ 3b
- NYHA class ≥ 3
- Decompensated insulin-dependent diabetes mellitus
- The need for inotropic and/or vasopressor support
- The presence of thrombolysis associated with an actual ischemic stroke
- Documented pneumonia within 3 months before randomization
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 15 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05335109
Start Date
January 1 2022
End Date
January 15 2024
Last Update
October 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
V.A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology
Moscow, Russia, 141534